SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000875320-23-000019
Filing Date
2023-08-01
Accepted
2023-08-01 16:03:38
Documents
13
Period of Report
2023-08-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K vrtx-20230801.htm   iXBRL 8-K 25391
2 EX-99.1 ex-991_q22023.htm EX-99.1 234971
  Complete submission text file 0000875320-23-000019.txt   413210

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT vrtx-20230801.xsd EX-101.SCH 1989
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT vrtx-20230801_lab.xml EX-101.LAB 24139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT vrtx-20230801_pre.xml EX-101.PRE 12595
7 EXTRACTED XBRL INSTANCE DOCUMENT vrtx-20230801_htm.xml XML 2720
Mailing Address 50 NORTHERN AVENUE BOSTON MA 02210
Business Address 50 NORTHERN AVENUE BOSTON MA 02210 6173416393
VERTEX PHARMACEUTICALS INC / MA (Filer) CIK: 0000875320 (see all company filings)

IRS No.: 043039129 | State of Incorp.: MA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-19319 | Film No.: 231131597
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences